Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Fineline Cube May 21, 2026
Company Deals

Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio

Fineline Cube May 21, 2026
Company Deals

Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows

Fineline Cube May 21, 2026
Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Fineline Cube May 21, 2026
Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Fineline Cube May 21, 2026
Company Deals

Shanghai’s Huangpu District Launches RMB Fund to Boost Fintech, AI, and Biotech Firms

Fineline Cube Jul 3, 2023

The South China Morning Post reports that the local government in Shanghai’s Huangpu district has...

Company Drug

Transcenta’s Osemitamab Combo Shows Promising PFS Data in Advanced GC/GEJ Cancer Study

Fineline Cube Jul 3, 2023

Transcenta Holding Ltd (HKG: 6628), a China-based biopharmaceutical company, has presented progression-free survival (PFS) data...

Company Drug

Hybio Pharmaceutical’s Liraglutide Biosimilar Withdrawn from NMPA Filing

Fineline Cube Jul 3, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...

Company Deals

Sinotau Pharmaceutical Secures Over RMB 1.1 Billion in Latest Financing Round

Fineline Cube Jul 3, 2023

Sinotau Pharmaceutical Group, a prominent nuclear medicine (radiopharmaceutical) company headquartered in Beijing, has reportedly raised...

Company Drug

Innovent Biologics and IASO Biotherapeutics’ Fucaso Approved for Multiple Myeloma Treatment in China

Fineline Cube Jul 3, 2023

Innovent Biologics, Inc. (HKG: 1801) and IASO Biotherapeutics have announced that they have received marketing...

Company Drug

SciClone Pharmaceuticals’ Danyelza Officially Launched in China for Neuroblastoma Treatment

Fineline Cube Jul 3, 2023

SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) has reached a significant milestone with the first prescription of...

Company Drug

Zai Lab’s Vyvgart Receives NMPA Approval as First-in-Class FcRn Antagonist for Myasthenia Gravis

Fineline Cube Jul 3, 2023

Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has announced that the...

Company Drug

InnoCare Pharma and Keymed Biosciences Initiate Clinical Trial for ICP-B02 with First Subcutaneous Injection

Fineline Cube Jul 3, 2023

InnoCare Pharma (HKG: 9969; SHA: 688428) and Keymed Biosciences Inc., (HKG: 2162) have announced a...

Company Drug

Jiangsu Hengrui Medicine Gets NMPA Approval for HRS-4357 Clinical Study in Prostate Cancer

Fineline Cube Jul 3, 2023

Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, has announced that...

Company Drug

Sichuan Biokin Pharmaceutical Gets FDA Approval for BL-B01D1 Clinical Study

Fineline Cube Jul 3, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Drug

RareStone Group’s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China

Fineline Cube Jul 3, 2023

The Center for Drug Evaluation (CDE) website in China has indicated that RareStone Group, a...

Company Drug

Joincare Pharmaceutical Initiates Phase III Study for Anti-IL-17A mAb in Plaque Psoriasis

Fineline Cube Jul 3, 2023

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced the initiation of a...

Company Medical Device

Bio-heart’s Iberis-HTN Study Shows Promising Results in Treating Primary Hypertension

Fineline Cube Jul 3, 2023

China-based Bio-heart Biological Technology Co., Ltd. (HKG: 2185) and its holding subsidiary Angiocare have announced...

Company Deals

Sisram Medical’s Alma Lasers Acquires PhotonMed International Ltd, Expanding Global Presence

Fineline Cube Jul 3, 2023

Sisram Medical Ltd (HKG: 1696), an Israel-based company and part of the Fosun Pharmaceutical Group...

Company Deals

Beijing Sun-Novo and Zhejiang Anglikang Enter Licensing Agreement for Hypertension Drug Candidate NHKC-1

Fineline Cube Jul 3, 2023

Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a significant licensing agreement with...

Company Drug

ZSP1273 by Guangdong Zhongsheng Pharma Shows Promise in Phase III Flu Treatment Study

Fineline Cube Jul 3, 2023

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a China-based pharmaceutical company, has announced preliminary top-line...

Company Drug

Hansoh Pharmaceutical’s Phenylheptal Peptide Receives NMPA Approval for Anemia Treatment

Fineline Cube Jul 3, 2023

The National Medical Products Administration (NMPA) has issued a marketing approval for China-based Hansoh Pharmaceutical...

Company Drug

Sinocelltech Group Receives NMPA Approval for Bevacizumab Biosimilar for Multiple Cancers

Fineline Cube Jun 30, 2023

China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received marketing approval from...

Company Deals

Cornerstone Robotics Secures RMB 800 Million in Funding for Surgical Robot Development

Fineline Cube Jun 30, 2023

Cornerstone Robotics, a leading surgical robot developer based in Shenzhen, has reportedly raised RMB 800...

Company Drug

Huadong Medicine Receives NMPA Approval for DR30206 Clinical Study in Advanced Solid Tumors

Fineline Cube Jun 30, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Posts pagination

1 … 511 512 513 … 669

Recent updates

  • Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate
  • Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up
  • Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network
  • Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma
  • Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate

Company Medical Device

Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up

Company Deals

Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network

Company Drug

Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.